Vaxcyte Reports $166.6 Million Net Loss in Q2 2025, Increases R&D Spending

Vaxcyte, Inc. reported a net loss of $166.6 million for the second quarter of 2025, compared to a loss of $128.7 million in the same period of 2024, marking a 29.4% increase year-over-year. For the first half of 2025, the company’s net loss totaled $307.3 million, up from $223.7 million in the prior year. The increase in losses is attributed to a significant rise in operating expenses, which reached $226.2 million for the quarter, a 47.9% increase from $153.0 million in Q2 2024. Research and development expenses surged by 47.7% to $194.2 million, driven by heightened activities related to the company's pneumococcal conjugate vaccine (PCV) programs.

In terms of financial position, Vaxcyte's total assets decreased to $3.3 billion as of June 30, 2025, down from $3.5 billion at the end of 2024. The company reported cash and cash equivalents of $306.7 million, alongside short-term investments of $1.4 billion. The accumulated deficit increased to $1.7 billion, reflecting the ongoing investment in research and development without any product revenue. The company’s total liabilities also rose to $234.0 million, up from $205.5 million at the end of 2024.

Strategically, Vaxcyte has made significant advancements in its clinical pipeline, particularly with its VAX-31 and VAX-24 vaccine candidates. The company announced positive topline results from a Phase 1/2 study of VAX-31 in adults, which has received breakthrough therapy designation from the FDA. Additionally, Vaxcyte has expanded its focus on its PCV franchise, pausing the development of other vaccine candidates, including VAX-A1 and VAX-GI, to allocate resources more effectively. The company also appointed Chris Griffith as Chief Business and Strategy Officer to enhance its strategic direction.

Operationally, Vaxcyte has increased its workforce to support its expanding clinical programs, with a notable rise in personnel-related costs contributing to the overall increase in general and administrative expenses, which grew by 49.2% in Q2 2025 compared to the previous year. The company continues to rely on third-party manufacturers for its vaccine production, with a significant agreement in place with Lonza for the construction of a dedicated manufacturing suite in Switzerland. This agreement is expected to bolster Vaxcyte's production capabilities as it prepares for potential commercial launches.

Looking ahead, Vaxcyte anticipates continued increases in research and development expenses as it advances its vaccine candidates through clinical trials and prepares for regulatory submissions. The company believes its existing cash and investments will be sufficient to fund operations for at least the next 12 months, but it will require additional capital to support its ongoing development efforts. The outlook remains contingent on the successful progression of its clinical trials and the eventual commercialization of its vaccine candidates.